{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:55:56Z","timestamp":1793832956552,"version":"4.6.1"},"reference-count":27,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>The aim of this study was to examine the safety and efficacy of 40 \u00b5m and 75 \u00b5m calibrated irinotecan-eluting beads (DEBIRI-TACE) for the treatment of colorectal cancer metastases. We conducted a retrospective review of 36 patients with unresectable liver metastases from colorectal cancer who were treated with DEBIRI-TACE between 2017 to 2020. Patients who received at least one session of DEBIRI were included in our analysis. A total of 105 DEBIRI sessions were completed. 86% of patients (n = 31) underwent one round of treatment, 14% of patients (n = 5) underwent two distinct rounds of treatment. The majority of patients were discharged the next day (92%, n = 33 patients) with no 30-day post-DEBIRI mortality. Five high-grade adverse events occurred, including longer stay for pain management (n = 2), postembolization syndrome requiring readmission (n = 2), and liver abscess (n = 1). The average survival from diagnosis of metastatic disease was 33.3 months (range 11\u201395, median 28). Nine of 36 patients are still alive (December 2020) and have an average follow-up time of 36.8 months from T0 (range 12\u201363, median 39). Small particle DEBIRI is safe and well-tolerated in the salvage setting, with outcomes comparable to that of larger bead sizes.<\/jats:p>","DOI":"10.3390\/curroncol29010020","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T01:15:26Z","timestamp":1641518126000},"page":"209-220","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes"],"prefix":"10.3390","volume":"29","author":[{"given":"Nicolas","family":"Voizard","sequence":"first","affiliation":[{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"},{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6257-1827","authenticated-orcid":false,"given":"Tiffany","family":"Ni","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"},{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Kiss","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Pugash","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"},{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Jonathon","family":"Raphael","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"},{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Coburn","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"},{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"David","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"},{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"key":"ref_1","unstructured":"(2021, November 28). Available online: Canadian-cancer-statistics-2019-en.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e198090","DOI":"10.1001\/jamanetworkopen.2019.8090","article-title":"National Trends in Colorectal Cancer Incidence Among Older and Younger Adults in Canada","volume":"2","author":"Brenner","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.3748\/wjg.v19.i46.8502","article-title":"Colorectal cancer: Current imaging methods and future perspectives for the diagnosis, staging and therapeutic response evaluation","volume":"19","author":"Kekelidze","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/gut.50.1.1","article-title":"Treatment of colorectal metastases: Surgery, cryotherapy, or radiofrequency ablation","volume":"50","author":"Primrose","year":"2002","journal-title":"Gut"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1245\/s10434-013-3297-7","article-title":"Cause of death from liver metastases in colorectal cancer","volume":"21","author":"Helling","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_6","first-page":"763245","article-title":"Ten-Year Survival after Liver Resection for Colorectal Metastases: Systematic Review and Meta-Analysis","volume":"2011","author":"Abbas","year":"2011","journal-title":"ISRN Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9531925","DOI":"10.1155\/2018\/9531925","article-title":"The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases","volume":"2018","author":"Gorgen","year":"2018","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_8","first-page":"651","article-title":"Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer","volume":"14","author":"Sinicrope","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clcc.2014.11.002","article-title":"A review of the evolution of systemic chemotherapy in the management of colorectal cancer","volume":"14","author":"Gustavsson","year":"2015","journal-title":"Clin. Colorectal. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"HEP16","DOI":"10.2217\/hep-2019-0010","article-title":"Updates of colorectal cancer liver metastases therapy: Review on DEBIRI","volume":"7","author":"Fiorentini","year":"2020","journal-title":"Hepatic Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3892\/ijo.2012.1572","article-title":"First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI)","volume":"41","author":"Eichler","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1002\/cncr.29534","article-title":"Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis","volume":"121","author":"Martin","year":"2015","journal-title":"Cancer"},{"key":"ref_13","first-page":"1387","article-title":"Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: Final results of a phase III study","volume":"32","author":"Fiorentini","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1007\/s00270-018-2017-x","article-title":"Transarterial Embolization with Small-Size Particles Loaded with Irinotecan for the Treatment of Colorectal Liver Metastases: Results of the MIRACLE III Study","volume":"41","author":"Mauri","year":"2018","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00270-014-1011-1","article-title":"Small versus large-sized drug-eluting beads (DEBIRI) for the treatment of hepatic colorectal metastases: A propensity score matching analysis","volume":"38","author":"Akinwande","year":"2015","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Tanaka, T., Sato, T., Nishiofuku, H., Masada, T., Tatsumoto, S., Marugami, N., Otsuji, T., Kanno, M., Koyama, F., and Sho, M. (2019). Selective TACE with irinotecan-loaded 40 \u03bcm microspheres and FOLFIRI for colorectal liver metastases: Phase I dose escalation pharmacokinetic study. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5862-3"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"20151060","DOI":"10.1259\/bjr.20151060","article-title":"Current strategies in interventional oncology of colorectal liver metastases","volume":"89","author":"Marko","year":"2016","journal-title":"Br. J. Radiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1007\/s00268-015-3386-9","article-title":"Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases","volume":"40","author":"Bhutiani","year":"2016","journal-title":"World J. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2217\/fon-2017-0025","article-title":"DEBIRI plus capecitabine: A treatment option for refractory liver-dominant metastases from colorectal cancer","volume":"15","author":"Basso","year":"2019","journal-title":"Future Oncol. Lond. Engl."},{"key":"ref_20","first-page":"4581","article-title":"Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead\u00ae, drug-eluting bead loaded with irinotecan: Results of a phase II clinical study","volume":"31","author":"Aliberti","year":"2011","journal-title":"Anticancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00270-018-02160-y","article-title":"Outcomes After Transarterial Embolization of Neuroendocrine Tumor Liver Metastases Using Spherical Particles of Different Sizes","volume":"42","author":"Zener","year":"2019","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jso.26270","article-title":"Safety and feasibility of initiating a hepatic artery infusion pump chemotherapy program for unresectable colorectal liver metastases: A multicenter, retrospective cohort study","volume":"123","author":"Muaddi","year":"2021","journal-title":"J. Surg. Oncol."},{"key":"ref_23","first-page":"578","article-title":"Expected and Unexpected Imaging Findings after 90Y Transarterial Radioembolization for Liver Tumors","volume":"39","author":"Spina","year":"2019","journal-title":"Radiogr. Rev. Publ. Radiol. Soc. N. Am. Inc"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","article-title":"First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): A combined analysis of three multicentre, randomised, phase 3 trials","volume":"18","author":"Wasan","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.clcc.2019.01.005","article-title":"FOLFOX and FOLFIRI use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data","volume":"18","author":"Neugut","year":"2019","journal-title":"Clin. Colorectal. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4251\/wjgo.v6.i6.156","article-title":"Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review","volume":"6","author":"Manceau","year":"2014","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria","volume":"25","author":"Choi","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/1\/20\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:36:30Z","timestamp":1760362590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/1\/20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,6]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["curroncol29010020"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29010020","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,6]]}}}